Therapeutic Asset Ratings
197 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
hdm2017
Neoplasm
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
P1
C
(37)
Hrs-6208
Neoplasm
Shandong Suncadia Medicine Co., Ltd.
P1
C
(37)
hs-20093
Solid Tumors
Hansoh BioMedical R&D Company
P1
C
(37)
hs-20110
Neoplasm
Hansoh BioMedical R&D Company
P1
C
(37)
hsk42360
Neoplasm
Haisco Pharmaceutical Group Co., Ltd.
P1
C
(37)
ibi3020
Neoplasm
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
P1
C
(37)
Immunoglobulin G1 [143-aspartic acid,236-glutamic acid], anti-(human cytotoxic T-lymphocyte-associated protein 4) (human monoclonal HBM4003 heavy chain V-D-J region) fusion protein with immunoglobulin G1 (human ?1-chain C region), dimer
Neoplasm
Harbour BioMed (Guangzhou) Co. Ltd.
P1
C
(37)
Inca036873
Neoplasm
Incyte Corporation
P1
C
(37)
Inca33890
Neoplasm
Incyte Corporation
P1
C
(37)
Incb123667
Neoplasm
Incyte Corporation
P1
C
(37)
Incb186748
Neoplasm
Incyte Corporation
P1
C
(37)
Infusion Of 4H11-28Z/Fil-12/Egfrt+ Genetically-Modified T Cells
Neoplasm
Memorial Sloan Kettering Cancer Center
P1
C
(37)
Intismeran
Neoplasm
ModernaTX, Inc.
P1
C
(37)
jr8603
Neoplasm
JiaRay Group
P1
C
(37)
Lutetium [177Lu] Bl-Arc001
Neoplasm
Sichuan Baili Pharmaceutical Co., Ltd.
P1
C
(37)
pep08
Neoplasm
PharmaEngine
P1
C
(37)
pf-07224826
Neoplasm
Pfizer
P1
C
(37)
pf-08046031
Neoplasm
Pfizer
P1
C
(37)
qls5316
Neoplasm
Qilu Pharmaceutical Co., Ltd.
P1
C
(37)
qtx3034
Neoplasm
Quanta Therapeutics
P1
C
(37)
ro7444973
Neoplasm
Hoffmann-La Roche
P1
C
(37)
Runimotamab
Neoplasm
Genentech, Inc.
P1
C
(37)
syh2051
Neoplasm
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
P1
C
(37)
sys6005
Neoplasm
CSPC Megalith Biopharmaceutical Co.,Ltd.
P1
C
(37)
Tak-103
Neoplasm
Takeda
P1
C
(37)
Showing 151 to 175 of 197 assets
Previous
Page 7 of 8
Next
